Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 3
1986 1
1987 3
1988 2
1989 3
1990 9
1991 8
1992 9
1993 8
1994 9
1995 8
1996 7
1997 14
1998 14
1999 12
2000 19
2001 18
2002 24
2003 52
2004 54
2005 87
2006 88
2007 114
2008 130
2009 153
2010 192
2011 228
2012 236
2013 325
2014 364
2015 388
2016 460
2017 454
2018 549
2019 563
2020 752
2021 511
Text availability
Article attribute
Article type
Publication date

Search Results

5,186 results
Results by year
Filters applied: . Clear all
Page 1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Zhang Y, et al. Among authors: zhu f. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.
Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L, Pei RJ, Li H, Ma XN, Zhou Y, Zhu FH, He PL, Tang W, Zhang YC, Xiong J, Xiao SQ, Tong XK, Zhang B, Zuo JP. Yang L, et al. Among authors: zhu fh. Acta Pharmacol Sin. 2021 Aug;42(8):1347-1353. doi: 10.1038/s41401-020-00556-6. Epub 2020 Oct 28. Acta Pharmacol Sin. 2021. PMID: 33116249 Free PMC article.
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J, Zhao F, Mao W, Sun J, Wang J, Han G, Li C, Xia Y, Seesaha PK, Zhu D, Li H, Zhang J, Wang G, Wang X, Li X, Shu Y. Chen X, et al. Among authors: zhu f. J Immunother Cancer. 2020 Nov;8(2):e001240. doi: 10.1136/jitc-2020-001240. J Immunother Cancer. 2020. PMID: 33172881 Free PMC article.
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. Deng M, et al. Among authors: zhu f. J Hematol Oncol. 2020 Nov 4;13(1):148. doi: 10.1186/s13045-020-00982-3. J Hematol Oncol. 2020. PMID: 33148342 Free PMC article.
Retiform hemangioendothelioma of the mandible: A case report.
Jiang J, Li X, Zhu F, He Y. Jiang J, et al. Among authors: zhu f. Oral Oncol. 2021 Apr;115:105120. doi: 10.1016/j.oraloncology.2020.105120. Epub 2020 Dec 17. Oral Oncol. 2021. PMID: 33342659 No abstract available.
Structure-based development of human antibody cocktails against SARS-CoV-2.
Wang N, Sun Y, Feng R, Wang Y, Guo Y, Zhang L, Deng YQ, Wang L, Cui Z, Cao L, Zhang YJ, Li W, Zhu FC, Qin CF, Wang X. Wang N, et al. Among authors: zhu fc. Cell Res. 2021 Jan;31(1):101-103. doi: 10.1038/s41422-020-00446-w. Epub 2020 Dec 1. Cell Res. 2021. PMID: 33262454 Free PMC article. No abstract available.
5,186 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page